Quantori Strengthens Global Leadership Team, Names Senior Business Leader Solman Rahman as Executive Vice President, Europe
8.9.2021 07:00:00 EEST | Business Wire | Press release
Quantori, a leading global provider of end-to-end software engineering, scientific informatics, data sciences and digital transformation services for life science and healthcare companies, today announced the appointment of Solman Rahman to Executive Vice President, Europe to support Quantori’s aggressive growth strategy and strengthen its market position as a premier global services provider.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005840/en/
Solman Rahman, Executive Vice President, Europe, Quantori (Photo: Business Wire)
“Solman’s wealth of experience in building and scaling business operations for leading technology consulting and digital platform engineering companies serving the European life science and healthcare markets makes him uniquely positioned to lead Quantori’s expansion in this key region,” said Richard Golob, CEO, Quantori. “Europe continues to be a powerhouse of world-class life science and biopharma industry innovation. We look forward to working with Solman in developing strategic client relationships to help biopharma and life science companies deliver critical technology programs and data management imperatives to accelerate development of novel therapeutics."
As Quantori’s Executive Vice President for Europe, Solman will be responsible for developing key partnerships within the EU region’s ecosystem of pharma and healthcare companies, in addition to ensuring delivery of superior services and providing leading technology capabilities to Quantori’s clients. Solman joins Quantori from EPAM Systems where he led the Northern Europe business and where he previously worked with Quantori leadership, including Richard Golob, who led EPAM’s Global Life Sciences Business into the fastest growing unit at EPAM, in addition to Dr. Yuriy Gankin, Quantori’s Chief Scientific Officer, and Vitaliy Aronov, Quantori’s Chief Technology Officer.
“I am thrilled to be rejoining such a brilliant executive team at a very exciting time in Quantori’s growth and development, especially as the European biopharma industry is scaling the use of digital technologies to enable the provision of precision medicines and personalized healthcare,” said Solman. “A major challenge in working with IT outsourcing companies is that they have a limited understanding of the life sciences and healthcare industries. One of Quantori’s key differentiators is its extensive domain knowledge underpinned by true scientific depth. This unique combination enables us to add considerable value from the outset and speed-to-market horsepower to the critical focus of today’s biopharma companies – to accelerate the translation of their research and data insights into a pipeline of new medicines.”
Prior to leading EPAM’s Northern European business, Solman worked at Cognizant in several roles, including serving as Head of Strategic Engagements and Industry Practice leadership. Solman began his career as an analyst at Cowen Inc. in the Technology Investment Banking Group, undertaking equity research in the biopharma and high-tech sectors. He currently serves as a board advisor to Conversationly, a digital agency leveraging messaging, automation and AI technologies to promote conversational commerce. He holds MSc and BSc degrees in Economics & Management and Econometrics from the London School of Economics and Political Science.
“We are thrilled to welcome Solman onboard, and he will be instrumental in our efforts to expand operations in Europe to help biopharma leaders bring novel and life-saving therapies to market through the powerful partnership of digital IT and R&D informatics,” said Yuriy Gankin, PhD, Quantori’s Chief Scientific and Strategy Officer.
About Quantori
Quantori is transforming life sciences and healthcare through the power of digital IT. Quantori develops end-to-end software engineering, scientific informatics, and data science solutions that help biopharma companies accelerate every stage of drug discovery and development. Quantori combines data engineering and advanced analytics with deep scientific domain knowledge to enable life science and healthcare organizations to achieve their digital transformations with greater speed and agility. Learn more about Quantori at www.quantori.com and connect on social media @Twitter, @LinkedIn, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005840/en/
Contact information
Heidi Creighton
heidi.creighton@quantori.com
Mobile/Text: 978-302-1198
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RS2 Financial Services GmbH Selected to Participate in ECB Digital Euro Pilot14.7.2026 15:22:00 EEST | Press release
RS2 Financial Services GmbH, an electronic money institution supervised by BaFin and part of the RS2 Group, operating under its innovation brand Beyond by RS2, has been selected to participate as an acquiring payment service provider in the Eurosystem’s digital euro pilot. The pilot marks the transition from technical preparation to practical validation, testing how a potential digital euro could function in everyday consumer and merchant payment scenarios. According to the official announcement of the European Central Bank, RS2 Financial Services GmbH is one of 36 payment service providers selected to participate in the programme. The participating organisations reflect a range of institution sizes, business models and markets across the euro area. RS2 Financial Services GmbH will contribute its expertise in acquiring and merchant payments to the pilot, leveraging the RS2 Group’s cloud-native payment technology and technical capabilities to support pilot execution. The Eurosystem plan
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 15:00:00 EEST | Press release
Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 2026,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “Dosing the first patient in our NAION trial marks a critical step in our mission to unlock the full potential of NGF. By advancing our proprietary intranasal NGF in clinical investigation, we are taking a bold, non-invasive approach that bypasses the blood-brain barrier and has the potential to redefine the standard of care.” NAION refers to a loss of blood flow to the optic nerve which causes rapid vision loss that u
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world applications that demonstrate the growing impact of geographic information system (GIS) technology. The first two other books starting the collection are Geowater: A Geographic Approach to Water Data and Forecasting and Parcels: How Property Shapes Geography. Together, these titles illustrate how spatial thinking and GIS are transforming how organizations understand systems, manage resources, and plan for the future. The Power of Where Collection reflects Esri’s ongoing commitment to helping organizations make smarter, more informed decisions across industries—on topics ranging from water sustainabi
Esri Helps Bring Up-to-Date Road Closure Information to Google Maps and Waze14.7.2026 15:00:00 EEST | Press release
Esri has expanded its Community Maps Program, enabling road closure data to be shared with Google Maps and Waze. The Road Closures solution, in Esri's ArcGIS platform, was introduced last year as a way for users to easily share road closure updates directly with popular consumer mapping providers so they can update their maps with this important information. The solution aimed to bridge the gap between government agencies managing timely road updates and the public, who rely on mapping apps for real-time navigation. Over 100 communities around the United States and other countries are actively sharing their road closure information. ArcGIS users can now easily share that same authoritative data with Google Maps and Waze via the Waze for Cities program. "For over a year, we've been working with dozens of our local government users to share their road closure information with our initial consumer mapping partners, Apple Maps and TomTom," said Deane Kensok, chief technology officer for Ar
CE-IVDR Mark for Hologic’s Aptima ® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 15:00:00 EEST | Press release
Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25% to 80%, with some showing stagnation or decline in recent years.3 “Despite the benefits of cervical cancer screening, there are still barriers
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom